MML Investors Services LLC grew its holdings in shares of Amgen (NASDAQ:AMGN) by 19.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 27,571 shares of the medical research company’s stock after purchasing an additional 4,490 shares during the period. MML Investors Services LLC’s holdings in Amgen were worth $4,795,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently made changes to their positions in AMGN. Lingohr & Partner Asset Management GmbH increased its position in shares of Amgen by 71.4% during the second quarter. Lingohr & Partner Asset Management GmbH now owns 8,165 shares of the medical research company’s stock valued at $1,340,000 after acquiring an additional 3,400 shares in the last quarter. Thrivent Financial For Lutherans grew its position in Amgen by 107.1% in the 2nd quarter. Thrivent Financial For Lutherans now owns 118,342 shares of the medical research company’s stock worth $20,382,000 after purchasing an additional 61,212 shares during the period. Verity Asset Management Inc. grew its position in Amgen by 363.8% in the 2nd quarter. Verity Asset Management Inc. now owns 8,989 shares of the medical research company’s stock worth $1,548,000 after purchasing an additional 7,051 shares during the period. Investec Asset Management LTD grew its position in Amgen by 1,081.7% in the 2nd quarter. Investec Asset Management LTD now owns 21,967 shares of the medical research company’s stock worth $3,783,000 after purchasing an additional 20,108 shares during the period. Finally, Fort L.P. bought a new stake in Amgen in the 2nd quarter worth approximately $4,294,000. 79.54% of the stock is owned by institutional investors.
Shares of AMGN stock opened at $171.38 on Tuesday. Amgen has a 1 year low of $152.16 and a 1 year high of $201.23. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35. The firm has a market cap of $114,595.02, a PE ratio of 13.62, a price-to-earnings-growth ratio of 2.10 and a beta of 1.36.
Amgen declared that its board has authorized a share repurchase plan on Thursday, February 1st that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the medical research company to buy shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.
The company also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be paid a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.08%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is 41.97%.
In related news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction on Friday, March 16th. The shares were sold at an average price of $189.75, for a total transaction of $289,368.75. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 4,575 shares of company stock worth $818,330. 0.19% of the stock is owned by corporate insiders.
A number of equities research analysts have commented on the stock. Argus raised shares of Amgen from a “hold” rating to a “buy” rating and lifted their target price for the stock from $192.33 to $220.00 in a research report on Tuesday, January 23rd. JPMorgan Chase lifted their target price on shares of Amgen from $184.00 to $189.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 24th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $189.00 target price on shares of Amgen in a research report on Wednesday, January 24th. Vetr downgraded shares of Amgen from a “hold” rating to a “sell” rating and set a $181.60 target price for the company. in a research report on Tuesday, March 6th. Finally, BMO Capital Markets lifted their target price on shares of Amgen from $192.00 to $202.00 and gave the stock a “market perform” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the stock. Amgen presently has a consensus rating of “Hold” and a consensus price target of $190.57.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.chaffeybreeze.com/2018/04/17/mml-investors-services-llc-acquires-4490-shares-of-amgen-amgn.html.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.